Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

FBRX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Forte Biosciences, Inc.NASDAQ: FBRX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $20.32M rose 62.0% year over year, behind the +123.8% change in trailing-twelve-month research & development. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at +118.4% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +62.0% toward the trailing-twelve-month pace of +123.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.32M-5.2% QoQ
Last fiscal yearDec 2025
$58.25M+174.8% YoY
LTMMar 2026
$65.43M+123.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+62.0%——
1 year+174.8%——
3-year CAGR+118.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
58.25M USD
Year-over-year change
+174.8%
4-year CAGR
+43.2%

Research & Development vs competitors

How FBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +123.8% is the highest of 10, against a peer median of -23.9%.
  • Over three fiscal years its annual growth of +118.4% compares with a peer median of -0.2%.
FBRX Competitors
Research & Development for FBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$114.68M USD-37.7%-16.4%622.7%
FATEFate Therapeutics, Inc.LTM Mar 2026$100.48M USD-23.9%-30.4%1590.8%
NKTXNkarta, Inc.LTM Mar 2026$88.91M USD-7.1%-0.2%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M USD+76.4%+63.2%—
FBRXForte Biosciences, Inc.LTM Mar 2026$65.43M USD+123.8%+118.4%—
PEPGPepGen Inc.LTM Mar 2026$58.35M USD-32.7%+9.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M USD-19.6%+9.2%6022.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$23.84M USD-29.5%+13.5%—
ACTUActuate Therapeutics IncLTM Mar 2026$9.64M USD-35.9%-14.4%—
Peer median (excluding FBRX) —-23.9%-0.2%1590.8%

Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue36K09K39K64K
Gross Profit(36K)0(9K)(39K)(64K)
Gross Margin—————
Research & Development13.85M5.59M21.86M21.19M58.25M
Selling, General & Admin7.63M8.3M10.62M15.37M12.41M
Operating Expenses21.49M13.9M32.48M36.56M70.66M
Depreciation & Amortization36K36K9K39K64K
EBITDA(21.67M)(13.84M)(31.47M)(35.44M)(68.27M)
EBITDA Margin—————
Operating Income(21.49M)(13.9M)(32.49M)(36.6M)(70.66M)
Operating Margin—————
Interest Income001.12M1.31M2.72M
Interest Expense00000
Other Income / Expenses(222K)17K1.01M1.12M2.32M
Income Before Tax(21.71M)(13.88M)(31.48M)(35.48M)(68.34M)
Pre-Tax Margin—————
Income Tax Expense00001.04M
Net Income(21.71M)(13.86M)(31.48M)(35.48M)(69.38M)
Net Margin—————
EPS (Basic)(38.85)(19.96)(24.92)(12.17)(4.71)
EPS (Diluted)(38.85)(19.96)(24.92)(12.17)(4.71)
Weighted Avg Shares558.71K695.34K1.26M2.92M147.18M
Weighted Avg Shares (Diluted)558.71K695.34K1.26M2.92M147.18M

Forte Biosciences, Inc.

NASDAQ:FBRX

Intrinsic Alpha fair value

Locked

Current Price

$76.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.